Passage Bio/$PASG
1D1W1MYTD1Y5YMAX
About Passage Bio
Passage Bio Inc is a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases. Their primary focus is the development and advancement of cutting-edge, one-time gene therapies designed to target critical underlying pathologies in these conditions. The Company operates in a single reportable segment, developing and advancing genetic medicines designed to target the critical underlying pathology of neurodegenerative diseases. The pipeline having PBFT02.
- Ticker
- $PASG
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 24
- Headquarters
- Philadelphia, United States
- Website
- www.passagebio.com
Passage Bio Metrics
BasicAdvanced
$14M
-
-$11.31
1.43
-
Price and volume
Market cap
$14M
Beta
1.43
52-week high
$20.00
52-week low
$3.29
Average daily volume
21K
Financial strength
Current ratio
1.215
Quick ratio
1.166
Profitability
EBITDA (TTM)
-37.579
Management effectiveness
Return on assets (TTM)
-45.62%
Return on equity (TTM)
-169.09%
Valuation
Price to book
3.13
Price to tangible book (TTM)
3.13
Price to free cash flow (TTM)
-0.413
Free cash flow yield (TTM)
-242.28%
Free cash flow per share (TTM)
-10.491
Growth
Earnings per share change (TTM)
-37.19%
3-year earnings per share growth (CAGR)
-34.92%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.